Answer
For first-line or maintenance treatment of advanced non-small-cell lung cancer, an activating EGFR mutation identifies tumours most likely to respond. A negative plasma test may require confirmation using tumour tissue where possible.
Sources for this answer
- Tarceva film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.